Nothing Special   »   [go: up one dir, main page]

SG11201605929RA - Diaryl macrocycles as modulators of protein kinases - Google Patents

Diaryl macrocycles as modulators of protein kinases

Info

Publication number
SG11201605929RA
SG11201605929RA SG11201605929RA SG11201605929RA SG11201605929RA SG 11201605929R A SG11201605929R A SG 11201605929RA SG 11201605929R A SG11201605929R A SG 11201605929RA SG 11201605929R A SG11201605929R A SG 11201605929RA SG 11201605929R A SG11201605929R A SG 11201605929RA
Authority
SG
Singapore
Prior art keywords
modulators
protein kinases
macrocycles
diaryl
diaryl macrocycles
Prior art date
Application number
SG11201605929RA
Inventor
Jingrong Jean Cui
Yishan Li
Evan W Rogers
Dayong Zhai
Original Assignee
Tp Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tp Therapeutics Inc filed Critical Tp Therapeutics Inc
Publication of SG11201605929RA publication Critical patent/SG11201605929RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
SG11201605929RA 2014-01-24 2015-01-23 Diaryl macrocycles as modulators of protein kinases SG11201605929RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461931506P 2014-01-24 2014-01-24
US201462049326P 2014-09-11 2014-09-11
US201562106301P 2015-01-22 2015-01-22
PCT/US2015/012597 WO2015112806A2 (en) 2014-01-24 2015-01-23 Diaryl macrocycles as modulators of protein kinases

Publications (1)

Publication Number Publication Date
SG11201605929RA true SG11201605929RA (en) 2016-08-30

Family

ID=53682127

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201605929RA SG11201605929RA (en) 2014-01-24 2015-01-23 Diaryl macrocycles as modulators of protein kinases
SG10202000191YA SG10202000191YA (en) 2014-01-24 2015-01-23 Diaryl macrocycles as modulators of protein kinases

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202000191YA SG10202000191YA (en) 2014-01-24 2015-01-23 Diaryl macrocycles as modulators of protein kinases

Country Status (32)

Country Link
US (6) US9714258B2 (en)
EP (6) EP4338739A3 (en)
JP (5) JP6490713B2 (en)
KR (1) KR102402179B1 (en)
CN (3) CN110317213B (en)
AP (1) AP2016009383A0 (en)
AU (2) AU2015209239B2 (en)
CA (1) CA2936079C (en)
CL (1) CL2016001876A1 (en)
CY (1) CY1121850T1 (en)
DK (3) DK3097107T3 (en)
EA (2) EA201892241A1 (en)
ES (3) ES2976459T3 (en)
FI (1) FI3636649T3 (en)
HK (1) HK1231407A1 (en)
HR (3) HRP20240503T1 (en)
HU (3) HUE066590T2 (en)
IL (2) IL246860B (en)
LT (3) LT3636649T (en)
MX (2) MX2016009588A (en)
MY (1) MY193524A (en)
NZ (2) NZ722375A (en)
PE (1) PE20160931A1 (en)
PH (1) PH12016501463A1 (en)
PL (3) PL3572416T3 (en)
PT (3) PT3097107T (en)
RS (3) RS63829B1 (en)
SG (2) SG11201605929RA (en)
SI (3) SI3097107T1 (en)
UA (1) UA121206C2 (en)
WO (1) WO2015112806A2 (en)
ZA (2) ZA201604654B (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
TWI577680B (en) 2008-10-22 2017-04-11 亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
SI3205654T1 (en) 2010-05-20 2019-07-31 Array Biopharma, Inc. Macrocyclic compounds as trk kinase inhibitors
DK3097107T3 (en) 2014-01-24 2019-07-08 Turning Point Therapeutics Inc DIARYL MACROCYCLES AS PROTEIN KINASAS MODULATORS
ES2941630T3 (en) 2014-11-16 2023-05-24 Array Biopharma Inc Hydrogen sulfate crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3- yl)-3-hydroxypyrrolidine-1-carboxamide
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
AU2016270803A1 (en) 2015-06-01 2018-01-04 Loxo Oncology, Inc. Methods of diagnosing and treating cancer
JP6871903B2 (en) * 2015-07-02 2021-05-19 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Chiral diallyl macrocyclic molecule as a modulator of protein kinase
PT3319969T (en) * 2015-07-06 2024-06-17 Turning Point Therapeutics Inc Diaryl macrocycle polymorph
MX2018000577A (en) 2015-07-16 2018-09-05 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors.
EP3733187B1 (en) 2015-07-21 2024-10-16 Turning Point Therapeutics, Inc. Chiral diaryl macrocycle and use thereof in the treatment of cancer
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US11278521B2 (en) 2015-12-15 2022-03-22 University Of South Florida GAS5 binding compounds, formulations, and uses thereof
WO2017176751A1 (en) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
LT3439663T (en) 2016-04-04 2024-10-10 Loxo Oncology, Inc. Methods of treating pediatric cancers
PE20190437A1 (en) 2016-05-18 2019-03-27 Loxo Oncology Inc PROCESSES FOR THE PREPARATION OF (S) -N- (5 - ((R) -2- (2,5-DIFLUOROPHENYL) PYRROLIDIN-1-IL) -PIRAZOLO [1,5-A] PYRIMIDIN-3-IL) - 3-HYDROXYPYRROLIDIN-1-CARBOXAMIDE AND SALTS THEREOF
US10689400B2 (en) * 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190092A1 (en) 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
ES2948194T3 (en) 2017-01-18 2023-09-01 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrazine compounds as RET kinase inhibitors
TWI808958B (en) * 2017-01-25 2023-07-21 美商特普醫葯公司 Combination therapy involving diaryl macrocyclic compounds
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
CN107586796B (en) * 2017-07-20 2021-08-06 暨明医药科技（苏州）有限公司 Synthesis method of (R) -2- (1-aminoethyl) -4-fluorophenol
EP3658148B1 (en) 2017-07-28 2024-07-10 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
TWI812649B (en) 2017-10-10 2023-08-21 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109516999B (en) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 Compounds useful as protein kinase modulators and uses thereof
EP3706749B1 (en) * 2017-11-10 2024-03-13 Angex Pharmaceutical, Inc. Macrocyclic compounds as trk kinase inhibitors and uses thereof
US20210087206A1 (en) 2017-12-19 2021-03-25 Turning Point Therapeutics, Inc. Macrocyclic kinase inhibitors and their use
DK3728271T3 (en) * 2017-12-19 2022-12-19 Turning Point Therapeutics Inc Macrocyclic compounds for the treatment of diseases
US11453672B2 (en) 2017-12-22 2022-09-27 Shenzhen Targetrx, Inc. Substituted pyrazolo[1,5-a]pyrimidines as tropomyosin receptor kinase inhibitors
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
TW201932464A (en) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 Substituted pyrazolyl[4,3-C]pyridine compounds as RET kinase inhibitors
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
WO2019144885A1 (en) * 2018-01-23 2019-08-01 深圳市塔吉瑞生物医药有限公司 Substituted pyrazolo[1,5-a]pyrimidine macrocyclic compound
CN111511749B (en) * 2018-01-30 2022-02-08 上海吉倍生物技术有限公司 Compounds having macrocyclic molecular structures and uses thereof
CN110156813B (en) * 2018-02-13 2023-07-25 北京诺诚健华医药科技有限公司 Heterocyclic compounds as TRK inhibitors
KR20200141041A (en) * 2018-03-28 2020-12-17 포천 파마슈티컬즈, 엘티디. Macrocyclic compounds as TRK kinase inhibitors
MA52218A (en) 2018-03-29 2021-02-17 Loxo Oncology Inc TREATMENT OF CANCERS ASSOCIATED WITH TRK
US11358973B2 (en) 2018-04-16 2022-06-14 Shenzhen Targetrx, Inc. Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity
US12129258B2 (en) 2018-04-25 2024-10-29 Primegene (Beijing) Co., Ltd Diaryl macrocyclic compound and pharmaceutical composition, and use thereof
WO2019210835A1 (en) * 2018-05-04 2019-11-07 正大天晴药业集团股份有限公司 Diaryl macrocyclic compound as protein kinase modulator
CN110627812B (en) 2018-06-25 2022-10-11 北京诺诚健华医药科技有限公司 Heterocyclic compounds as TRK inhibitors
CA3224985A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
CN112996794A (en) 2018-09-10 2021-06-18 阿雷生物药品公司 Fused heterocyclic compounds as RET kinase inhibitors
CN110950889B (en) * 2018-09-27 2022-04-05 北京赛林泰医药技术有限公司 Multi-target kinase inhibitor and preparation method and application thereof
US20210403485A1 (en) * 2018-09-29 2021-12-30 Shandong Luye Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivative as selective trk inhibitor
EP4461734A2 (en) 2018-10-22 2024-11-13 Alumis Inc. Tyk2 inhibitors and uses thereof
CN111171049B (en) * 2018-11-09 2021-06-04 山东轩竹医药科技有限公司 Tyrosine kinase inhibitors and uses thereof
JP7190036B2 (en) * 2018-11-09 2022-12-14 シャントン、シュアンチュー、ファーマ、カンパニー、リミテッド MACROCYCLIC TYROSINE KINASE INHIBITOR AND USE THEREOF
US20220112201A1 (en) * 2018-11-19 2022-04-14 Dana-Farber Cancer Institute, Inc. Macrocyclic inhibitors of dyrk1a
EP3898615A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
JP2022515198A (en) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド Substituted pyrazolo [1,5-a] pyridine compound as an inhibitor of FGFR tyrosine kinase
CN111592541B (en) * 2019-02-21 2021-09-10 山东轩竹医药科技有限公司 Macrocyclic kinase inhibitors and uses thereof
US20220177486A1 (en) * 2019-03-11 2022-06-09 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
JP7318009B2 (en) * 2019-05-21 2023-07-31 浙江海正薬業股▲ふん▼有限公司 Macrolide derivative, production method and use thereof
WO2020257165A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
WO2020257189A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for treating disease
US20220411439A1 (en) * 2019-06-19 2022-12-29 Turning Point Therapeutics, Inc. Polymorphs of a macrocyclic kinase inhibitor
MX2021015770A (en) * 2019-06-21 2022-04-12 Janssen Pharmaceutica Nv Macrocyclic inhibitors of mcl-1.
CN113773335A (en) * 2019-06-21 2021-12-10 成都海博为药业有限公司 Compound as protein kinase inhibitor and preparation method and application thereof
WO2021027503A1 (en) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 Tricyclic compound, preparation method therefor, and intermediate and use thereof
WO2021063276A1 (en) * 2019-09-30 2021-04-08 浙江海正药业股份有限公司 Macrocyclic derivative, preparation method therefor and use thereof
BR112022010278A2 (en) 2019-11-27 2022-10-04 Turning Point Therapeutics Inc COMBINED THERAPY INVOLVING MACROCYCLIC DIARIL COMPOUNDS
EP4065395A4 (en) 2019-11-27 2024-02-14 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds
AU2020395136A1 (en) 2019-12-03 2022-07-07 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
US20230101747A1 (en) 2019-12-06 2023-03-30 Schrödinger, Inc. Cyclic compounds and methods of using same
BR112022012684A2 (en) 2019-12-27 2023-03-07 Schroedinger Inc CYCLIC COMPOUNDS AND METHODS OF THEIR USE
CN113045587A (en) * 2019-12-27 2021-06-29 成都倍特药业股份有限公司 Crystal form of macrocyclic compound and preparation method thereof
CN113135938B (en) * 2020-01-19 2022-06-14 山东轩竹医药科技有限公司 Substituted macrocyclic tyrosine kinase inhibitors and uses thereof
AU2021229457A1 (en) * 2020-03-02 2022-10-20 Turning Point Therapeutics, Inc. Therapeutic uses of macrocyclic compounds
US20230183265A1 (en) * 2020-05-08 2023-06-15 Shandong Xuanzhu Pharma Co., Ltd. Crystal Form of Macrocyclic Tyrosine Kinase Inhibitor and Preparation Method therefor
US20230219978A1 (en) * 2020-06-04 2023-07-13 Scinnohub Pharmaceutical Co., Ltd Compound having macrocyclic structure and use thereof
BR112023000463A2 (en) * 2020-07-10 2023-03-28 Blossomhill Therapeutics Inc MACROCYCLES AND THEIR USE
EP4211140A1 (en) 2020-09-10 2023-07-19 Schrödinger, Inc. Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
JP2024505890A (en) 2021-01-26 2024-02-08 シュレーディンガー， インコーポレイテッド Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
WO2022182845A1 (en) * 2021-02-25 2022-09-01 Blossomhill Therapeutics, Inc. Macrocycles and their use
TW202300150A (en) 2021-03-18 2023-01-01 美商薛定諤公司 Cyclic compounds and methods of using same
WO2023078267A1 (en) * 2021-11-02 2023-05-11 赛诺哈勃药业（成都）有限公司 Amino-containing macrocyclic compound as protein kinase modulator
EP4460498A1 (en) * 2022-01-05 2024-11-13 Blossomhill Therapeutics, Inc. Macrocyclic compounds and use as kinase inhibitors
CN115746023B (en) * 2022-10-27 2024-08-09 复旦大学 Heterocyclic macrocyclic compound containing indazole structure as protein kinase inhibitor and preparation method thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
EP0281841B1 (en) 1987-03-07 1990-11-14 Bayer Ag Process for preparation of 5-amino-4,6-dihalogenopyridines
PT690843E (en) 1993-03-25 2001-01-31 Upjohn Co SUBSTITUTED INDOOR DERIVATIVES WITH FORMILY OR CYAN OWNING DOPAMINERGIC ACTIVITY
FR2746309B1 (en) 1996-03-22 1998-04-17 Oreal COMPOSITION FOR DYEING KERATIN FIBERS CONTAINING PYRAZOLOPYRIMIDINEOXO; THEIR USE FOR DYEING AS COUPLER, DYEING PROCESSES
RS49779B (en) 1998-01-12 2008-06-05 Glaxo Group Limited, Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors
FR2793791B1 (en) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot NOVEL INHIBITOR COMPOUNDS SPECIFIC TO A2 PHOSPHOLIPASES
ES2250459T3 (en) 2000-07-31 2006-04-16 F. Hoffmann-La Roche Ag PIPERAZINE DERIVATIVES
WO2002076925A2 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
WO2004052315A2 (en) 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
KR20110073500A (en) * 2008-09-08 2011-06-29 메르크 파텐트 게엠베하 Macrocyclics pyrimidines as aurora kinase inhibitors
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
TWI577680B (en) 2008-10-22 2017-04-11 亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
PE20110828A1 (en) 2008-10-31 2011-11-22 Genentech Inc PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
US20110029480A1 (en) * 2009-08-03 2011-02-03 IntelliCubes, Inc. Method of Compiling Multiple Data Sources into One Dataset
JP5643332B2 (en) 2009-12-07 2014-12-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
WO2011071716A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
SA111320200B1 (en) 2010-02-17 2014-02-16 ديبيوفارم اس ايه Bicyclic Compounds and their Uses as Dual C-SRC / JAK Inhibitors
SI3205654T1 (en) * 2010-05-20 2019-07-31 Array Biopharma, Inc. Macrocyclic compounds as trk kinase inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
EP2508607A1 (en) * 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
EP2744336B1 (en) * 2011-08-19 2017-07-05 Merck Sharp & Dohme Corp. Process and intermediates for preparing macrolactams
WO2013045702A2 (en) 2011-09-29 2013-04-04 L'oreal Dye composition comprising a non-glycosyl iridoid compound and a specific nucleophile or an amino or thio polymer, dyeing process, and device therefor
WO2013045701A2 (en) 2011-09-29 2013-04-04 L'oreal Dyeing process using a composition comprising a glycosyl iridoid compound and a nucleophile or an amino or thio polymer, composition and devices therefor
ES2569048T3 (en) 2011-09-30 2016-05-06 Oncodesign S.A. FLT3 macrocyclic kinase inhibitors
JP6073343B2 (en) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Substituted bicyclic azaheterocycles and analogs as sirtuin regulators
PL2822953T3 (en) 2012-03-06 2017-07-31 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
KR101965025B1 (en) 2012-03-09 2019-04-02 렉시컨 파마슈티컬스 인코퍼레이티드 PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
AU2013230119B2 (en) * 2012-03-09 2017-02-23 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
CN104936956A (en) 2013-01-30 2015-09-23 拜耳制药股份公司 Amino-substituted isothiazoles
CN105358534A (en) 2013-04-23 2016-02-24 斯洛文尼亚莱柯制药股份有限公司 Novel synthetic process to 8-chloro-1-methyl-benzo[d]azepine, novel intermediates and the production thereof
US20160159808A1 (en) 2013-07-24 2016-06-09 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
DK3097107T3 (en) * 2014-01-24 2019-07-08 Turning Point Therapeutics Inc DIARYL MACROCYCLES AS PROTEIN KINASAS MODULATORS
WO2016070241A1 (en) 2014-11-03 2016-05-12 Ctxt Pty Ltd Triazine compounds, compositions and synthesis
MX2017007748A (en) 2014-12-15 2018-01-30 Cmg Pharmaceutical Co Ltd Fused ring heteroaryl compounds and their use as trk inhibitors.
US9981944B2 (en) 2015-02-20 2018-05-29 Rigel Pharmaceuticals, Inc GDF-8 inhibitors
WO2016144844A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Carboxamide inhibitors of irak4 activity
WO2016144846A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
EP3292107A1 (en) 2015-05-05 2018-03-14 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
JP6871903B2 (en) 2015-07-02 2021-05-19 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Chiral diallyl macrocyclic molecule as a modulator of protein kinase
PT3319969T (en) 2015-07-06 2024-06-17 Turning Point Therapeutics Inc Diaryl macrocycle polymorph
EP3733187B1 (en) 2015-07-21 2024-10-16 Turning Point Therapeutics, Inc. Chiral diaryl macrocycle and use thereof in the treatment of cancer
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
MX2018010678A (en) 2016-03-04 2019-01-17 Univ Vanderbilt Substituted indole mcl-1 inhibitors.
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
WO2018112027A1 (en) 2016-12-14 2018-06-21 Development Center For Biotechnology Antibody-drug conjugates and uses thereof
TWI808958B (en) 2017-01-25 2023-07-21 美商特普醫葯公司 Combination therapy involving diaryl macrocyclic compounds
EP3658148B1 (en) 2017-07-28 2024-07-10 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof

Also Published As

Publication number Publication date
AU2015209239A1 (en) 2016-07-14
US10246466B2 (en) 2019-04-02
CA2936079C (en) 2022-07-19
WO2015112806A3 (en) 2015-11-12
CA2936079A1 (en) 2015-07-30
CN110317214A (en) 2019-10-11
PT3636649T (en) 2024-04-09
DK3636649T3 (en) 2024-05-21
ES2976459T3 (en) 2024-08-01
EP3572416B1 (en) 2022-09-21
AU2019279951A1 (en) 2020-01-16
HK1231407A1 (en) 2017-12-22
EP3097107A2 (en) 2016-11-30
US20200216465A1 (en) 2020-07-09
RS59059B1 (en) 2019-08-30
MX2016009588A (en) 2017-05-15
SI3636649T1 (en) 2024-07-31
WO2015112806A2 (en) 2015-07-30
PL3636649T3 (en) 2024-05-06
KR20160111395A (en) 2016-09-26
US20170334929A1 (en) 2017-11-23
US10618912B2 (en) 2020-04-14
FI3636649T3 (en) 2024-05-02
PH12016501463B1 (en) 2017-02-06
LT3097107T (en) 2019-07-25
EP3636648A1 (en) 2020-04-15
JP2022133462A (en) 2022-09-13
EP3572416A1 (en) 2019-11-27
JP2021063121A (en) 2021-04-22
US20220112213A1 (en) 2022-04-14
SI3097107T1 (en) 2019-08-30
CN110317213B (en) 2022-10-18
CN110317213A (en) 2019-10-11
US20170002023A1 (en) 2017-01-05
PE20160931A1 (en) 2016-09-21
PT3572416T (en) 2022-12-06
LT3572416T (en) 2022-12-27
EP3636649B1 (en) 2024-02-14
EP3097107B1 (en) 2019-04-17
ES2735729T3 (en) 2019-12-20
PL3572416T3 (en) 2023-02-27
KR102402179B1 (en) 2022-05-25
CN110317214B (en) 2022-11-22
CN106170289B (en) 2019-07-23
JP7356546B2 (en) 2023-10-04
US20240140964A1 (en) 2024-05-02
US20190169207A1 (en) 2019-06-06
AP2016009383A0 (en) 2016-08-31
IL268820B (en) 2021-10-31
EP4338739A2 (en) 2024-03-20
EA201892241A1 (en) 2019-02-28
EP3636650A1 (en) 2020-04-15
HUE045208T2 (en) 2019-12-30
SG10202000191YA (en) 2020-03-30
MY193524A (en) 2022-10-18
HUE060554T2 (en) 2023-03-28
EA201691492A1 (en) 2017-06-30
HRP20221518T1 (en) 2023-02-17
LT3636649T (en) 2024-04-10
SI3572416T1 (en) 2023-02-28
ZA202004100B (en) 2023-12-20
JP6490713B2 (en) 2019-03-27
US9714258B2 (en) 2017-07-25
AU2019279951B2 (en) 2021-08-12
JP2019104748A (en) 2019-06-27
CL2016001876A1 (en) 2017-02-03
RS65417B1 (en) 2024-05-31
IL246860B (en) 2019-09-26
CN106170289A (en) 2016-11-30
NZ722375A (en) 2022-11-25
UA121206C2 (en) 2020-04-27
PH12016501463A1 (en) 2017-02-06
JP2023179539A (en) 2023-12-19
EP3097107A4 (en) 2017-08-09
EA031863B1 (en) 2019-03-29
EP4338739A3 (en) 2024-05-29
MX2020001360A (en) 2020-03-20
PT3097107T (en) 2019-07-19
IL268820A (en) 2019-10-31
NZ761094A (en) 2023-02-24
CY1121850T1 (en) 2020-07-31
IL246860A0 (en) 2016-08-31
EP3636649A1 (en) 2020-04-15
ZA201604654B (en) 2020-10-28
HUE066590T2 (en) 2024-08-28
PL3097107T3 (en) 2020-01-31
HRP20191283T1 (en) 2019-10-18
JP2017503867A (en) 2017-02-02
DK3572416T3 (en) 2022-12-12
AU2015209239B2 (en) 2019-09-12
RS63829B1 (en) 2023-01-31
ES2933350T3 (en) 2023-02-06
HRP20240503T1 (en) 2024-07-05
DK3097107T3 (en) 2019-07-08

Similar Documents

Publication Publication Date Title
IL268820B (en) Diaryl macrocycles as modulators of protein kinases
IL256377A (en) Chiral diaryl macrocycles as modulators of protein kinases
IL283582A (en) Modulators of ror-gamma
IL280905A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
HK1256599A1 (en) Modulators of ror-gamma
IL247234A0 (en) Modulators of caspase-6
EP3338775A4 (en) Use of butylidenephthalide
SG11201607445QA (en) Methods of modulating wars2
PT3377106T (en) Modulation of ciliogenesis
GB201418230D0 (en) Construction of surfaces